Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

fi-aventis made a $10 million investment in Regulus, providing external establishment of the significant value of our Regulus ownership.  Overall the progress we and our partners have made this year provide a snapshot of the potential of our technology and our pipeline as well as the significant upside for Isis as our partners continue to advance the drugs in our pipeline.  Already this year, we have earned more than $65 million from our partnerships," concluded Ms. Parshall.

Drug Development and Corporate Highlights

  • Mipomersen is being developed by Isis and Genzyme for patients at high cardiovascular risk who cannot adequately control their cholesterol levels with current therapies.  Mipomersen has been shown to substantially lower LDL-C as well as lowering other atherogenic lipids linked to cardiovascular disease, including apoB, Lp(a), triglycerides and VLDL.  Isis and Genzyme completed the four Phase 3 studies that are planned to be included in the initial U.S. and E.U. filings for marketing approval for mipomersen.  These filings, expected in the first half of 2011, will seek approval for the treatment of patients with homozygous FH, and may also include patients with severe heterozygous FH.  Genzyme is also planning for filings in markets beyond the U.S. and E.U.
  • Isis reported data on mipomersen from two Phase 3 studies that met all primary, secondary and tertiary endpoints.
  • In the first Phase 3 study evaluating mipomersen in patients with severe hypercholesterolemia, Isis and Genzyme reported that the study met its primary endpoint with a 36 percent reduction in LDL-C compared with a 13 percent increase in placebo.
  • In the second Phase 3 study evaluating mipomersen in patients with high cholesterol at high risk for developing coronary heart disease, Isis and Genzyme reported that the study met its primary endpoint with a 37 percent reduction in LDL-C compared with a 5 percent decrea
    '/>"/>

  • SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
    (Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
    (Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
    ... BURLINGTON, Mass., Dec. 12, 2011 /PRNewswire-iReach/ -- ... Financial. Tom joined Ametros as executive vice president in ... in the workers, compensation managed care industry. He served ... Medical, vice president of national occupational health for Kaiser ...
    ... Ontario, Dec. 12, 2011  Valeant Pharmaceuticals International, Inc. ... at a special meeting of shareholders of Afexa ... today in Calgary, Alberta, the shareholders of Afexa ... subsidiary, 1625907 Alberta Ltd. (the " Offeror ") ...
    Cached Medicine Technology:Ametros Financial Names Thomas Ash as CEO 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 3
    (Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
    (Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
    (Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
    (Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
    (Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
    ... the arm by way of a novel research conducted by ... endowed with the potential to inhibit the growth of blood ... may throw open a plethora of options to fight cancer ... University, previous research has indicated the benefits of aspirin in ...
    ... down for decades, ever since studies showed a strong link ... experts have suggested that some people should aim even lower, ... called low-density lipoprotein for some high-risk people — even if ... there. ,Not so fast, says a team of researchers ...
    ... Among patients with schizophrenia whose medication is changed ... antipsychotic drugs do not appear to offer significant ... a report in the October issue of Archives ... ,The findings run contrary to the ...
    ... less than 2,000 grams (about 4.5 pounds) at birth ... the average teenager to have physical and mental difficulties, ... Archives of Pediatrics & Adolescent Medicine, one of the ... increase the risk for major disabilities such as cerebral ...
    ... unexplored regions of the human genome are thousands of ... growth of breast cancer is driven by estrogen, new ... ,In the October issue of Nature Genetics, the investigators ... panels" -- stretches of DNA that turn genes on ...
    ... has apologized to a woman who had a miscarriage in ... to go through the process.// ,On Tuesday Health region ... are sorry that this situation occurred and we empathize with ... the circumstances of this case, as we do with all ...
    Cached Medicine News:Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 2Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 3Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 4Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Low Birth Weight Babies May Have Mental & Physical Problems 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: